Jilin Aodong Pharmaceutical Group Co Ltd (000623) - Net Assets

Latest as of September 2025: CN¥30.82 Billion CNY ≈ $4.51 Billion USD

Based on the latest financial reports, Jilin Aodong Pharmaceutical Group Co Ltd (000623) has net assets worth CN¥30.82 Billion CNY (≈ $4.51 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥34.58 Billion ≈ $5.06 Billion USD) and total liabilities (CN¥3.76 Billion ≈ $550.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Jilin Aodong Pharmaceutical Group Co Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥30.82 Billion
% of Total Assets	89.13%
Annual Growth Rate	20.53%
5-Year Change	24.45%
10-Year Change	66.53%
Growth Volatility	34.96

Jilin Aodong Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2024)

This chart illustrates how Jilin Aodong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Jilin Aodong Pharmaceutical Group Co Ltd for the complete picture of this company's asset base.

Annual Net Assets for Jilin Aodong Pharmaceutical Group Co Ltd (1993–2024)

The table below shows the annual net assets of Jilin Aodong Pharmaceutical Group Co Ltd from 1993 to 2024. For live valuation and market cap data, see Jilin Aodong Pharmaceutical Group Co Ltd market capitalisation.

Year	Net Assets	Change
2024-12-31	CN¥29.28 Billion ≈ $4.28 Billion	+6.48%
2023-12-31	CN¥27.50 Billion ≈ $4.02 Billion	+4.40%
2022-12-31	CN¥26.34 Billion ≈ $3.85 Billion	+5.20%
2021-12-31	CN¥25.04 Billion ≈ $3.66 Billion	+6.42%
2020-12-31	CN¥23.53 Billion ≈ $3.44 Billion	+4.83%
2019-12-31	CN¥22.44 Billion ≈ $3.28 Billion	+5.65%
2018-12-31	CN¥21.24 Billion ≈ $3.11 Billion	+3.45%
2017-12-31	CN¥20.54 Billion ≈ $3.01 Billion	+8.81%
2016-12-31	CN¥18.87 Billion ≈ $2.76 Billion	+7.34%
2015-12-31	CN¥17.58 Billion ≈ $2.57 Billion	+38.90%
2014-12-31	CN¥12.66 Billion ≈ $1.85 Billion	+18.80%
2013-12-31	CN¥10.66 Billion ≈ $1.56 Billion	+9.25%
2012-12-31	CN¥9.75 Billion ≈ $1.43 Billion	+7.24%
2011-12-31	CN¥9.09 Billion ≈ $1.33 Billion	+25.52%
2010-12-31	CN¥7.25 Billion ≈ $1.06 Billion	+10.45%
2009-12-31	CN¥6.56 Billion ≈ $959.99 Million	+27.56%
2008-12-31	CN¥5.14 Billion ≈ $752.55 Million	+5.09%
2007-12-31	CN¥4.89 Billion ≈ $716.08 Million	+137.10%
2006-12-31	CN¥2.06 Billion ≈ $302.01 Million	+22.05%
2005-12-31	CN¥1.69 Billion ≈ $247.45 Million	+3.62%
2004-12-31	CN¥1.63 Billion ≈ $238.80 Million	+20.80%
2003-12-31	CN¥1.35 Billion ≈ $197.69 Million	+10.30%
2002-12-31	CN¥1.22 Billion ≈ $179.23 Million	+3.60%
2001-12-31	CN¥1.18 Billion ≈ $173.01 Million	+6.76%
2000-12-31	CN¥1.11 Billion ≈ $162.06 Million	+53.73%
1999-12-31	CN¥720.42 Million ≈ $105.42 Million	+13.30%
1998-12-31	CN¥635.85 Million ≈ $93.04 Million	+91.24%
1997-12-31	CN¥332.48 Million ≈ $48.65 Million	+36.79%
1996-12-31	CN¥243.07 Million ≈ $35.57 Million	+135.94%
1995-12-31	CN¥103.02 Million ≈ $15.07 Million	+29.05%
1994-12-31	CN¥79.83 Million ≈ $11.68 Million	-10.99%
1993-12-31	CN¥89.69 Million ≈ $13.12 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jilin Aodong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1978450091500.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥19.78 Billion	68.16%
Common Stock	CN¥1.20 Billion	4.12%
Other Comprehensive Income	CN¥7.30 Billion	25.15%
Other Components	CN¥746.80 Million	2.57%
Total Equity	CN¥29.03 Billion	100.00%

Jilin Aodong Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Jilin Aodong Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company	Market Cap
Thai Oil Public Company Limited BK:TOP	$3.29 Billion
National Beverage Corp NASDAQ:FIZZ	$3.29 Billion
WesBanco Inc NASDAQ:WSBC	$3.29 Billion
Cohen & Steers Inc NYSE:CNS	$3.29 Billion
WNS Holdings Ltd NYSE:WNS	$3.29 Billion
GKG Precision Machine Co. Ltd. A SHE:301338	$3.29 Billion
Bains Mer Monaco PA:BAIN	$3.29 Billion
Clicks JSE:CLS	$3.28 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jilin Aodong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 27,211,602,992 to 29,027,588,245, a change of 1,815,985,253 (6.7%).
Net income of 1,551,393,071 contributed positively to equity growth.
Dividend payments of 1,059,989,000 reduced retained earnings.
Share repurchases of 300,004,613 reduced equity.
Other comprehensive income increased equity by 148,663,903.
Other factors increased equity by 1,475,921,892.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥1.55 Billion	+5.34%
Dividends Paid	CN¥1.06 Billion	-3.65%
Share Repurchases	CN¥300.00 Million	-1.03%
Other Comprehensive Income	CN¥148.66 Million	+0.51%
Other Changes	CN¥1.48 Billion	+5.08%
Total Change	CN¥-	6.67%

Book Value vs Market Value Analysis

This analysis compares Jilin Aodong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.76x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 212.37x to 0.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
1995-12-31	CN¥0.09	CN¥18.79	x
1996-12-31	CN¥0.21	CN¥18.79	x
1997-12-31	CN¥0.29	CN¥18.79	x
1998-12-31	CN¥0.50	CN¥18.79	x
1999-12-31	CN¥0.57	CN¥18.79	x
2000-12-31	CN¥0.92	CN¥18.79	x
2001-12-31	CN¥0.98	CN¥18.79	x
2002-12-31	CN¥0.91	CN¥18.79	x
2003-12-31	CN¥1.02	CN¥18.79	x
2004-12-31	CN¥1.12	CN¥18.79	x
2005-12-31	CN¥1.19	CN¥18.79	x
2006-12-31	CN¥1.53	CN¥18.79	x
2007-12-31	CN¥3.96	CN¥18.79	x
2008-12-31	CN¥4.16	CN¥18.79	x
2009-12-31	CN¥5.37	CN¥18.79	x
2010-12-31	CN¥6.18	CN¥18.79	x
2011-12-31	CN¥7.77	CN¥18.79	x
2012-12-31	CN¥8.29	CN¥18.79	x
2013-12-31	CN¥9.07	CN¥18.79	x
2014-12-31	CN¥10.84	CN¥18.79	x
2015-12-31	CN¥14.95	CN¥18.79	x
2016-12-31	CN¥16.22	CN¥18.79	x
2017-12-31	CN¥17.46	CN¥18.79	x
2018-12-31	CN¥18.09	CN¥18.79	x
2019-12-31	CN¥17.39	CN¥18.79	x
2020-12-31	CN¥18.30	CN¥18.79	x
2021-12-31	CN¥19.75	CN¥18.79	x
2022-12-31	CN¥20.02	CN¥18.79	x
2023-12-31	CN¥22.87	CN¥18.79	x
2024-12-31	CN¥24.66	CN¥18.79	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jilin Aodong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.34%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 59.43%
• Asset Turnover: 0.08x
• Equity Multiplier: 1.14x
Recent ROE (5.34%) is below the historical average (13.11%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
1995	25.18%	14.98%	0.70x	2.40x	CN¥15.63 Million
1996	16.30%	16.33%	0.58x	1.73x	CN¥15.32 Million
1997	26.89%	27.06%	0.59x	1.68x	CN¥56.17 Million
1998	13.87%	22.16%	0.43x	1.44x	CN¥22.77 Million
1999	15.02%	26.02%	0.32x	1.78x	CN¥33.54 Million
2000	7.54%	25.80%	0.22x	1.33x	CN¥-26.40 Million
2001	2.83%	7.28%	0.29x	1.36x	CN¥-81.99 Million
2002	7.12%	13.17%	0.30x	1.77x	CN¥-30.54 Million
2003	8.37%	14.71%	0.35x	1.65x	CN¥-19.23 Million
2004	8.96%	14.24%	0.33x	1.93x	CN¥-13.61 Million
2005	8.00%	14.40%	0.30x	1.82x	CN¥-27.66 Million
2006	27.44%	63.25%	0.26x	1.69x	CN¥309.63 Million
2007	43.23%	235.73%	0.15x	1.22x	CN¥1.53 Billion
2008	17.79%	92.86%	0.16x	1.19x	CN¥377.18 Million
2009	21.84%	133.25%	0.14x	1.14x	CN¥740.67 Million
2010	17.24%	111.17%	0.14x	1.10x	CN¥519.93 Million
2011	21.98%	173.07%	0.11x	1.12x	CN¥1.08 Billion
2012	6.68%	44.72%	0.13x	1.13x	CN¥-320.81 Million
2013	10.01%	54.11%	0.16x	1.14x	CN¥1.25 Million
2014	11.21%	62.97%	0.16x	1.09x	CN¥152.57 Million
2015	14.92%	111.09%	0.12x	1.14x	CN¥855.71 Million
2016	8.94%	60.89%	0.13x	1.09x	CN¥-197.42 Million
2017	9.18%	62.60%	0.14x	1.08x	CN¥-166.50 Million
2018	4.45%	28.13%	0.13x	1.17x	CN¥-1.17 Billion
2019	6.31%	45.45%	0.12x	1.16x	CN¥-821.31 Million
2020	7.32%	75.89%	0.08x	1.17x	CN¥-626.43 Million
2021	7.16%	77.29%	0.08x	1.17x	CN¥-705.45 Million
2022	6.84%	62.09%	0.09x	1.20x	CN¥-822.86 Million
2023	5.36%	42.33%	0.11x	1.19x	CN¥-1.26 Billion
2024	5.34%	59.43%	0.08x	1.14x	CN¥-1.35 Billion

Industry Comparison

This section compares Jilin Aodong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $1,126,644,093
Average return on equity (ROE) among peers: 7.89%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	CN¥30.82 Billion	25.18%	0.12x	$3.29 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$205.69 Million	15.10%	2.12x	$1.05 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$765.24 Million	1.30%	0.72x	$438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$1.12 Billion	13.25%	0.26x	$5.06 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.01 Billion	1.03%	0.58x	$2.76 Billion
Wedge Industrial Co Ltd (000534)	$551.68 Million	1.40%	0.01x	$2.94 Billion
Yunnan Baiyao Group Co Ltd (000538)	$740.30 Million	23.15%	0.72x	$13.74 Billion
Hainan Haiyao Co Ltd (000566)	$317.39 Million	7.74%	0.74x	$958.72 Million
Tus Pharmaceutical Group Co Ltd (000590)	$271.26 Million	1.07%	1.01x	$386.52 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$5.16 Billion	6.95%	1.96x	$1.04 Billion

About Jilin Aodong Pharmaceutical Group Co Ltd

SHE:000623 China Drug Manufacturers - Specialty & Generic

Market Cap

$3.29 Billion

CN¥22.47 Billion CNY

Market Cap Rank

#4708 Global

#880 in China

Share Price

CN¥18.79

Change (1 day)

-0.63%

52-Week Range

CN¥16.17 - CN¥21.82

All Time High

CN¥24.39